Greenwood Capital Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Greenwood Capital Associates’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$320K	Buy	+5,585	New	+$306K	0.03%	265
2019 Q2	–	Sell	-6,197	Closed	-$550K	–	176
2019 Q1	$550K	Buy	6,197 +745	+14%	+$69K	0.14%	88
2018 Q4	$464K	Buy	5,452 +798	+17%	+$75.9K	0.12%	100
2018 Q3	$451K	Sell	4,654 -15	-0.3%	-$1.5K	0.1%	114
2018 Q2	$440K	Buy	4,669 +415	+10%	+$36.3K	0.1%	108
2018 Q1	$345K	Buy	4,254 +395	+10%	+$33.9K	0.08%	129
2017 Q4	$344K	Sell	3,859 -1,875	-33%	-$163K	0.08%	143
2017 Q3	$534K	Sell	5,734 -165	-3%	-$14.6K	0.13%	104
2017 Q2	$536K	Buy	5,899 +337	+6%	+$30.7K	0.14%	102
2017 Q1	$488K	Buy	5,562 +1,272	+30%	+$113K	0.13%	110
2016 Q4	$355K	Sell	4,290 -240	-5%	-$20.6K	0.1%	121
2016 Q3	$419K	Buy	+4,530	New	+$427K	0.13%	106
2015 Q3	–	Sell	-1,530	Closed	-$209K	–	157
2015 Q2	$209K	Buy	+1,530	New	+$190K	0.06%	149

Other funds holding BMRN

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

AIM

ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Greenwood Capital Associates's BMRN Position: Q2 2026 in Review

Greenwood Capital Associates opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 5,585 shares worth $320K. The stake represents 0.03% of the portfolio and ranks #265 among its holdings. This is a return to the name: Greenwood Capital Associates previously reported a position in BMRN as recently as Q1 2019.

Greenwood Capital Associates first reported a position in BMRN in Q2 2015 and has held it in 13 quarters since. The position peaked at $550K in Q1 2019. 162 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Greenwood Capital Associates held 5,585 shares of BioMarin Pharmaceuticals worth $320K as of Q2 2026.
BioMarin Pharmaceuticals was a new Greenwood Capital Associates position in Q2 2026.
BioMarin Pharmaceuticals made up 0.03% of Greenwood Capital Associates's portfolio in Q2 2026, its #265 holding.
Greenwood Capital Associates first reported a position in BioMarin Pharmaceuticals in Q2 2015 and has held it in 13 quarters since.
Greenwood Capital Associates's BioMarin Pharmaceuticals position peaked at $550K in Q1 2019.
162 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Greenwood Capital Associates's 13F filing for Q2 2026, filed 28 Jul 2026.